Thozhukat Sathyapalan

Summary

Affiliation: Hull York Medical School
Country: UK

Publications

  1. ncbi Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome
    Thozhukat Sathyapalan
    Michael White Diabetes Centre, 220 236 Analby Road, Hull Royal Infirmary, Hull, HU3 2JZ, United Kingdom
    J Clin Endocrinol Metab 97:3951-5. 2012
  2. ncbi Recent advances in cardiovascular aspects of polycystic ovary syndrome
    T Sathyapalan
    Hull York Medical School, Academic Endocrinology, Diabetes and Metabolism, Michael White Diabetes Centre, 220 236 Anlaby Road, Hull, UK
    Eur J Endocrinol 166:575-83. 2012
  3. ncbi Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study
    Thozhukat Sathyapalan
    Department of Diabetes, Endocrinology and Metabolism, Hull York Medical School, UK
    Ann Clin Biochem 49:80-5. 2012
  4. ncbi Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes?
    T Sathyapalan
    Unit of Endocrinology and Metabolism, Hull York Medical School, Hull, UK
    Minerva Endocrinol 36:147-56. 2011
  5. ncbi High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome
    Thozhukat Sathyapalan
    Department of Endocrinology, Diabetes and Metabolism, Hull York Medical School, Michael White Diabetes Centre, Hull Royal Infirmary, 220 236 Anlaby Road, Hull, HU3 2RW UK
    Nutr J 9:55. 2010
  6. ncbi Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes
    Thozhukat Sathyapalan
    Department of Diabetes, Endocrinology and Metabolism, Hull York Medical School, Hull, U K
    Diabetes Care 33:1948-50. 2010
  7. ncbi Mediators of inflammation in polycystic ovary syndrome in relation to adiposity
    Thozhukat Sathyapalan
    Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Michael White Diabetes Centre, 220 236 Analby Road, Hull Royal Infirmary, Hull HU32JZ, UK
    Mediators Inflamm 2010:758656. 2010
  8. ncbi The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study
    Thozhukat Sathyapalan
    Department of Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull HU3 2JZ, United Kingdom
    J Clin Endocrinol Metab 96:1442-9. 2011
  9. ncbi A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study
    Thozhukat Sathyapalan
    Department of Diabetes and Endocrinology, University of Hull, Hull, UK
    Clin Endocrinol (Oxf) 69:931-5. 2008
  10. ncbi Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome
    Thozhukat Sathyapalan
    Department of Diabetes, Endocrinology and Metabolism, Hull York Medical School, Hull, UK
    Clin Chem 56:1696-700. 2010

Collaborators

Detail Information

Publications17

  1. ncbi Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome
    Thozhukat Sathyapalan
    Michael White Diabetes Centre, 220 236 Analby Road, Hull Royal Infirmary, Hull, HU3 2JZ, United Kingdom
    J Clin Endocrinol Metab 97:3951-5. 2012
    ..Statins are considered to have a pleiotropic effect other than their lipid-lowering effect. These effects may be mediated in part by reducing oxidative stress...
  2. ncbi Recent advances in cardiovascular aspects of polycystic ovary syndrome
    T Sathyapalan
    Hull York Medical School, Academic Endocrinology, Diabetes and Metabolism, Michael White Diabetes Centre, 220 236 Anlaby Road, Hull, UK
    Eur J Endocrinol 166:575-83. 2012
    ..It focuses on some recent important data that has emerged while also exposing the gaps that remain in our knowledge that need to be addressed...
  3. ncbi Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study
    Thozhukat Sathyapalan
    Department of Diabetes, Endocrinology and Metabolism, Hull York Medical School, UK
    Ann Clin Biochem 49:80-5. 2012
    ..It has been shown that atorvastatin reduces testosterone concentrations in patients with PCOS. The objective was to study the effect of atorvastatin on serum androstenedione and DHEAS concentrations in patients with PCOS...
  4. ncbi Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes?
    T Sathyapalan
    Unit of Endocrinology and Metabolism, Hull York Medical School, Hull, UK
    Minerva Endocrinol 36:147-56. 2011
    ....
  5. ncbi High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome
    Thozhukat Sathyapalan
    Department of Endocrinology, Diabetes and Metabolism, Hull York Medical School, Michael White Diabetes Centre, Hull Royal Infirmary, 220 236 Anlaby Road, Hull, HU3 2RW UK
    Nutr J 9:55. 2010
    ..The effect of polyphenol rich chocolate in subjects with chronic fatigue syndrome (CFS) has not been studied previously...
  6. ncbi Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes
    Thozhukat Sathyapalan
    Department of Diabetes, Endocrinology and Metabolism, Hull York Medical School, Hull, U K
    Diabetes Care 33:1948-50. 2010
    ..This study compared the effect of equivalent LDL-lowering doses of simvastatin and atorvastatin on hsCRP in type 2 diabetic patients...
  7. ncbi Mediators of inflammation in polycystic ovary syndrome in relation to adiposity
    Thozhukat Sathyapalan
    Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Michael White Diabetes Centre, 220 236 Analby Road, Hull Royal Infirmary, Hull HU32JZ, UK
    Mediators Inflamm 2010:758656. 2010
    ..In this paper, the potential relationships between fat distribution, adipocyte dysfunction and, altered inflammatory markers in patients with PCOS have been discussed...
  8. ncbi The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study
    Thozhukat Sathyapalan
    Department of Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull HU3 2JZ, United Kingdom
    J Clin Endocrinol Metab 96:1442-9. 2011
    ..There is concern whether soy phytoestrogens may affect thyroid function. If true, soy phytoestrogens may be expected to have a greater impact in subjects with subclinical hypothyroidism...
  9. ncbi A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study
    Thozhukat Sathyapalan
    Department of Diabetes and Endocrinology, University of Hull, Hull, UK
    Clin Endocrinol (Oxf) 69:931-5. 2008
    ..Rimonabant has been found to reduce weight and improve the metabolic profile in patients with obesity, type 2 diabetes and metabolic syndrome...
  10. ncbi Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome
    Thozhukat Sathyapalan
    Department of Diabetes, Endocrinology and Metabolism, Hull York Medical School, Hull, UK
    Clin Chem 56:1696-700. 2010
    ....
  11. ncbi Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS)
    Thozhukat Sathyapalan
    Department of Diabetes and Endocrinology, University of Hull, Hull, UK
    Clin Endocrinol (Oxf) 70:124-8. 2009
    ..This study was undertaken to determine if subsequent metformin treatment after rimonabant would maintain the improvement in weight, insulin resistance and hyperandrogenaemia in PCOS...
  12. ncbi Does equol production determine soy endocrine effects?
    Dana Shor
    Hull York Medical School, Hull, UK
    Eur J Nutr 51:389-98. 2012
    ..In Western countries, 30-50% of individuals metabolize daidzein into equol and are known as equol producers. Equol production may be the source of benefit from isoflavones in endocrine disease...
  13. ncbi The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism
    Hassan Kahal
    Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK
    Clin Endocrinol (Oxf) 76:196-200. 2012
    ..With increased biochemical screening, primary hyperparathyroidism (pHPT) is often discovered incidentally whilst patients are asymptomatic...
  14. ncbi Evidence for statin therapy in polycystic ovary syndrome
    Thozhukat Sathyapalan
    Stephen L Atkin Diabetes, Endocrinology and Metabolism, Hull York Medical School, Hull, UK
    Ther Adv Endocrinol Metab 1:15-22. 2010
    ..In this review, the effect of statins on PCOS is discussed with reference to the underlying potential mechanism of action...
  15. ncbi Radiotherapy-induced hypopituitarism: a review
    Thozhukat Sathyapalan
    Department of Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, University of Hull, Hull, UK
    Expert Rev Anticancer Ther 12:669-83. 2012
    ..The clinical management of hypopituitarism is challenging both for the patients and healthcare providers. Here we have reviewed the scale of the problem, the risk factors and the management of RIH...
  16. ncbi Pharmacological treatment of obesity in patients with polycystic ovary syndrome
    Hassan Kahal
    Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull HU3 2RW, UK
    J Obes 2011:402052. 2011
    ..Weight reduction plays an integral part in the management of women with PCOS. In this paper, current available weight reduction therapies in the management of PCOS are discussed...
  17. ncbi Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
    Alireza M Manuchehri
    Department of Endocrinology, Diabetes and Metabolism, University of Hull, Hull, UK
    Pituitary 10:261-6. 2007
    ..Dopamine agonists (DA) may act on prolactinoma size and secretion through additional effects on adenoma vascularity that can be visualized using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)...